Tamoxifen for relapse of ovarian cancer-Reference-Cited by-同舟云学术

Tamoxifen for relapse of ovarian cancer

Published:2010-03-17 Issue:11 Volume:2020 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Williams Chris¹,Simera Iveta²,Bryant Andrew³

Affiliation:

1. Cochrane Gynaecological, Neuro-oncology and Orphan Cancers; Royal United Hospital; Bath UK

2. Centre for Statistics in Medicine; NDORMS, University of Oxford; Oxford UK

3. Institute of Health & Society; Newcastle University; Newcastle upon Tyne UK

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD001034.pub2/fullpdf

Reference48 articles.

1. Oestrogen receptor expression is a common feature of ovarian borderline tumors;Abu-Jawdeh;Gynecologic Oncology,1996

2. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program;Ahlgren;Journal of Clinical Oncology,1993

3. High-dose tamoxifen: extended palliation in patients with chemoresistant epithelial ovarian cancer;Ahlgren;American Society of Clinical Oncology,1993

4. Correlation between steroid hormone receptors, histological and clinical parameters in ovarian carcinoma;Anderl;Gynecology and Obstetrics Investigations,1988

5. Tamoxifen responsiveness, hormone receptors, and tumor grade: a prospective study;Beecham;Gynecologic Oncology,1988

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options;Biomedicines;2023-08-01

2. Berlin, im Februar 2022 – Tamoxifen-Lieferengpass: Eine Stellungnahme der Fachgesellschaft;Geburtshilfe und Frauenheilkunde;2022-04

3. Tamoxifen – Lieferengpass: Eine Stellungnahme der Fachgesellschaft;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2022-03

4. Analysis of Prediagnostic Circulating Levels of Gonadotropins and Androgens with Risk of Epithelial Ovarian Cancer;Journal of Laboratory Physicians;2022-01-18

5. Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial–mesenchymal transition;Open Life Sciences;2022-01-01